Search Results - "Byrne, C.D"

Omega-3 Fatty Acids, Hepatic Lipid Metabolism, and Nonalcoholic Fatty Liver Disease by SCORLETTI, E, BYRNE, C. D

“…Long-chain omega-3 fatty acids belong to a family of polyunsaturated fatty acids that are known to have important beneficial effects on metabolism and…”
Get full text

Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? by Targher, G, Marchesini, G, Byrne, C.D

“…Abstract Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related…”
Get full text

Global epidemiology of nonalcoholic fatty liver disease: Meta‐analytic assessment of prevalence, incidence, and outcomes by Lonardo, A., Byrne, C.D., Caldwell, S.H., Cortez‐Pinto, H., Targher, G.

Get full text

Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis by Mantovani, A., Lonardo, A., Vinco, G., Zoppini, G., Lippi, G., Bonora, E., Loomba, R., Tilg, H., Byrne, C.D., Fabbri, L., Targher, G.

“…Recent observational studies assessed the association between non-alcoholic fatty liver disease (NAFLD) and lung function in adults, but the magnitude of this…”
Get full text

Lipoprotein (a), metabolic syndrome and coronary calcium score in a large occupational cohort by Sung, K.-C, Wild, S.H, Byrne, C.D

“…Abstract Background and aims Whether lipoprotein (a) [Lp(a)] concentration is associated with metabolic syndrome (MetS) and pre-clinical atherosclerosis in…”
Get full text

Grip strength and the metabolic syndrome: findings from the Hertfordshire Cohort Study by Sayer, A.A., Syddall, H.E., Dennison, E.M., Martin, H.J., Phillips, D.I.W., Cooper, C., Byrne, C.D.

“…Introduction: Sarcopenia, the loss of muscle mass and strength with age, is significantly associated with type 2 diabetes in older people. Aim: To determine…”
Get full text

Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease by Scorletti, E, Bhatia, L, McCormick, K.G, Clough, G.F, Nash, K, Calder, P.C, Byrne, C.D

“…Abstract Background Non-alcoholic fatty liver disease (NAFLD) represents a range of liver conditions from simple fatty liver to progressive end stage liver…”
Get full text

Corrigendum to “Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease” [Contemp Clin Trials 37 (2) (2014) 301–311] by Scorletti, E, Bhatia, L, McCormick, K.G, Clough, G.F, Nash, K, Calder, P.C, Byrne, C.D

Get full text

Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials by Mantovani, A., Byrne, C.D., Scorletti, E., Mantzoros, C.S., Targher, G.

“…There are no approved drugs for the treatment of non-alcoholic fatty liver disease (NAFLD). However, many randomized controlled trials (RCT) have examined the…”
Get full text

Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men by Waterworth, D.M., Talmud, P.J., Luan, J., Flavell, D.M., Byrne, C.D., Humphries, S.E., Wareham, N.J.

“…Variation in the insulin responsive element (IRE) of the APOC3 promoter has been shown to be associated with insulin and glucose concentrations after an oral…”
Get full text

Utilising pancreatic exocrine insufficiency in the detection of resectable pancreatic ductal adenocarcinoma by McDonnell, D., Afolabi, P.R., Wilding, S., Swann, J.R., Byrne, C.D., Hamady, Z.Z.

Get full text

Metabolite changes associated with resectable pancreatic ductal adenocarcinoma: a study using nuclear magnetic resonance spectroscopy and mass spectrometry analyses by McDonnell, D., Afolabi, P.R., Wilding, S., Swann, J.R., Byrne, C.D., Hamady, Z.Z.

Get full text

Patients with diabetes are at higher risk for severe illness from COVID-19 by Targher, G., Mantovani, A., Wang, X.-B., Yan, H.-D., Sun, Q.-F., Pan, K.-H., Byrne, C.D., Zheng, K.I., Chen, Y.-P., Eslam, M., George, J., Zheng, M.-H.

“…•It is currently uncertain whether people with diabetes are at higher risk of severe illness from coronavirus disease 2019 (COVID-19).•We found that diabetes…”
Get full text

Physical Activity and Incident Pancreatic Cancer: Results from the UK Biobank Prospective Cohort by Assarian, B.A., Byrne, C.D., McDonnell, D., Hamady, Z.

Get full text

The Plasma Glutamine: Glucose Ratio as a Diagnostic Test for Pancreatic Ductal Adenocarcinoma by McDonnell, D., Byrne, C.D., Wilding, S., Swann, J.R., Frampton, A.E., Merali, N., Hamady, Z.Z.

Get full text

Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes by Mantovani, A., Turino, T., Lando, M.G., Gjini, K., Byrne, C.D., Zusi, C., Ravaioli, F., Colecchia, A., Maffeis, C., Salvagno, G., Lippi, G., Bonora, E., Targher, G.

“…Despite the high prevalence and serious clinical implications of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM),…”
Get full text

Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes by Mantovani, A., Sani, E., Fassio, A., Colecchia, A., Viapiana, O., Gatti, D., Idolazzi, L., Rossini, M., Salvagno, G., Lippi, G., Zoppini, G., Byrne, C.D., Bonora, E., Targher, Giovanni

“…Information is lacking on the association between non-alcoholic fatty liver disease (NAFLD) and bone mineral density (BMD) or circulating bone turnover…”
Get full text

Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease by Mantovani, A., Zusi, C., Sani, E., Colecchia, A., Lippi, G., Zaza, G.L., Valenti, L., Byrne, C.D., Maffeis, C., Bonora, E., Targher, G.

“…Evidence is emerging that PNPLA3 rs738409 polymorphism (the major genetic variant associated with susceptibility to non-alcoholic fatty liver disease [NAFLD])…”
Get full text

Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography by Mantovani, A., Bonapace, S., Lunardi, G., Canali, G., Dugo, C., Vinco, G., Calabria, S., Barbieri, E., Laaksonen, R., Bonnet, F., Byrne, C.D., Targher, G.

“…Recent prospective studies have identified distinct plasma ceramides as strong predictors of major adverse cardiovascular events in patients with established…”
Get full text

Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease by Mantovani, A., Lunardi, G., Bonapace, S., Dugo, C., Altomari, A., Molon, G., Conti, A., Bovo, C., Laaksonen, R., Byrne, C.D., Bonnet, F., Targher, G.

“…Plasma levels of certain ceramides are increased in patients with ischemic heart disease (IHD). Many risk factors for IHD are also risk factors for chronic…”
Get full text